This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Emergencies
:: Organization Announcements
:: Journal Watch
GAVI COVAX Advance Market Commitment Summit 2022

One Third of Humanity Still Unvaccinated, Secretary-General Tells GAVI COVAX Advance Market Commitment Summit 2022, Citing ‘Deeply Unequal World’
8 April 2022
SG/SM/21233
Following is the text of UN Secretary-General António Guterres’ video message for the GAVI COVAX Advance Market Commitment Summit 2022, ”One World Protected - Break COVID Now”, in New York today:
I commend the Government of Germany and GAVI for organizing this important Summit. This gathering is a critical reminder that the COVID-19 pandemic is far from over.

We’re seeing 1.5 million new cases each day. Large outbreaks are spreading in Asia. A new wave is sweeping across Europe. And some countries are reporting their highest death rates since the start of the pandemic.

Omicron is a startling reminder of how quickly COVID-19 can mutate and spread, especially in the absence of high vaccination coverage. Some high-income countries are preparing for their second booster doses. And yet one third of humanity remains unvaccinated. This is a brutal indictment of our deeply unequal world. It’s also a prime breeding ground for new variants, more deaths and increased human and economic misery. The next variant is not a question of “if”. It’s a question of “when”.

We are far from our target of every country reaching 70 per cent vaccination coverage by the middle of this year. And with new variants emerging every four months on average, time is of the essence. Supply is not the issue. Manufacturers are producing 1.5 billion doses per month. And thanks to its remarkable procurement, shipment and delivery system, the COVAX Facility and its Advance Market Commitment mechanism has managed to deliver 1.2 billion doses so far to countries in need.

This proves that progress is possible. But, the window is closing fast. Governments and pharmaceutical companies need to work better together to deliver vaccines to every person, everywhere — not just in wealthy countries. This means countries fulfilling and accelerating dose-sharing and donation commitments to COVAX with better quality of supply. And it means having strong national vaccine-delivery systems at the ready — including efforts to counter misinformation and get vaccines into arms.

I also call on countries to commit new funding for the ACT-Accelerator and COVAX this year. And we need to help all countries prepare for future pandemics by multiplying the number of countries able to locally produce tests, vaccines and treatments. So, we can save lives quickly and equitably when the next variant or pandemic strikes. And ultimately, build stronger health systems that are accessible to all.
Investments today will not only save lives. They will strengthen overwhelmed health systems for the future, and help all countries move closer to sustainable recovery. The COVID-19 pandemic is not over. But, it can be. Let’s end it together.

---

**World leaders commit US$ 4.8 billion to help Break COVID Now**

- 2022 Break COVID Now Summit co-hosted by Gavi, alongside Germany (G7 President), Ghana, Indonesia (G20 President), and Senegal (African Union chair) reaffirms support for COVAX and global solidarity in fighting the COVID-19 pandemic
- **Summit sees US$ 4.8 billion in commitments, securing vital cash to help lower-income countries boost vaccinations now**, secure equitable access for new vaccine procurements plus additional help for countries looking to procure their own vaccines in the future. Indonesia’s President, leading the G20 this year, extended his support for the launch of the Pandemic Vaccine Pool as a key instrument for response and resiliency.
- Professor José Manuel Barroso, Chair of the Gavi Board, said: “We welcome this incredible show of global solidarity from so many stakeholders at a time when the world faces multiple challenges.”

Geneva, 8 April 2022 – The 2022 Break COVID Now Summit, co-hosted by Gavi, the Vaccine Alliance alongside the governments of Germany, Ghana, Indonesia and Senegal saw world leaders come together to reaffirm support for equitable access to COVID-19 vaccines and acting urgently to break COVID now.

With Germany, Indonesia and Senegal holding Presidencies in the G7, G20 and AU respectively, the **Summit represented an affirmation of the international community’s support for COVAX’s multilateral approach to vaccine equity**. The event also successfully secured commitments valued at US$ 4.8 billion for the Gavi COVAX Advance Market Commitment (AMC), the mechanism which supports equitable access to COVID-19 vaccines for lower-income countries.

These commitments mean a total of US$ 1.7 billion in new sovereign donor pledges towards the 2022 AMC fundraising ask, as well as US$ 2.1 billion worth of commitments via new innovative financial mechanisms provided by the EIB and the United States Development Finance Corporation (DFC), and least US$ 1 billion made available by three multilateral development banks (MDBs) – World Bank, Asian Development Bank and European Investment Bank (EIB).

**The commitments made will enable COVAX to provide urgent delivery support for lower-income countries and ensure dose donations can be shipped and administered.** They have also enabled Gavi to launch the Pandemic Vaccine Pool to support future procurement of new COVID-19 vaccines, on behalf of COVAX AMC participants, should they be needed. Commitments from MDBs enable low-cost financing for these countries to purchase additional vaccines beyond those that are donor-funded.

**New donor commitments made to the Gavi COVAX AMC include:**
- Japan, co-host of the 2021 AMC Summit, pledged US$ 500 million
- Germany, co-host of today’s Break COVID Now Summit, pledged EUR 400 million
- Canada pledged CAD 220 million
- Brazil pledged US$ 86.7 million
- European Commission EUR 75 million
- Australia pledged AUD 85 million
- Finland pledged EUR 2 million
- Iceland pledged ISK 250 million
- Luxembourg pledged EUR 1 million
- Vietnam pledged US$ 500,000
- Regional Government of Catalonia, Spain pledged EUR 290’000
- Provincial Council of Bizkaia, Spain pledged EUR 100’000
- Estonia pledged EUR 40,000
- Malta pledged EUR 40,000
- Workday Foundation pledged US$ 300,000
- CODE(RED) Campaign pledged US$ 200,000
- Other donors also pledged a total of US$ 122.6 million

The pledges made today build on top of the commitments made at the 2022 One World Protected event, which launched the 2022 AMC Investment Opportunity on 19 January.

A number of countries and groups expressed intention to make additional contributions to COVAX, including in support of the Pandemic Vaccine Pool, but were unable to announce today due to their budgetary processes and the short timeline of this emergency appeal...

---

**IMF Working Paper**

**A Global Strategy to Manage the Long-Term Risks of COVID-19**

Authors/Editors: Ruchir Agarwal; Gita Gopinath; Jeremy Farrar; Richard Hatchett; Peter Sands

Publication Date: April 5, 2022 :: 26 pages


**Summary:**

The pandemic is not over, and the health and economic losses continue to grow. It is now evident that COVID-19 will be with us for the long term, and there are very different scenarios for how it could evolve, from a mild endemic scenario to a dangerous variant scenario. This realization calls for a new strategy that manages both the uncertainty and the long-term risks of COVID-19. There are four key policy implications of such a strategy.

First, we need to achieve equitable access beyond vaccines to encompass a comprehensive toolkit.

Second, we must monitor the evolving virus and dynamically upgrade the toolkit.

Third, we must transition from the acute response to a sustainable strategy toward COVID-19, balanced and integrated with other health and social priorities.

Fourth, we need a unified risk-mitigation approach to future infectious disease threats beyond COVID-19.

Infectious diseases with pandemic potential are a threat to global economic and health security. The international community should recognize that its pandemic financing addresses a systemic risk to the global economy, not just the development need of a particular country. Accordingly, it should allocate additional funding to fight pandemics and strengthen health systems both domestically and overseas. This will require about $15 billion in grants this year and $10 billion annually after that.

Series: Working Paper No. 2022/068
New IMF Staff Paper Strategy to Manage the Long-Term Risks of COVID-19
April 5, 2022
Washington, DC: The International Monetary Fund, in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), the Global Fund, and Wellcome Trust published today “A Global Strategy to Manage the Long-term Risks of COVID-19” working paper, which calls for a more comprehensive and integrated pandemic response from the international community.

In the joint paper, the four global organizations assert that ending the pandemic everywhere remains an urgent economic, health, and moral priority for the world—advocating for the following:

**Gita Gopinath, First Deputy Managing Director, IMF:**

“It is now clear that COVID-19 is likely to be with us for the long-term. Given the many possible scenarios for the evolution of COVID-19 (from benign to severe scenarios), and given the limited resources countries have, we need a new strategy.

“Countries need a more comprehensive COVID-19 toolkit for fighting the pandemic that includes vaccines, tests, treatments—and bolstering the resilience of health systems so they are in a better position to tackle both COVID-19 and other deadly diseases in a sustainable, effective way.

“Overall, health security is economic security. As recently as our January World Economic Outlook Update, we’d estimated the cumulative losses from the pandemic to reach $13.8 trillion. The international community should recognize that its pandemic financing addresses a systemic risk to the global economy. Thus, we are calling for additional funding to fight pandemics and to strengthen health systems. **This will require about $15 billion in grants this year and $10 billion annually after that.** The cost of inaction – for all of us – is very high. We need to act – now.

“Together with our partners on the Multilateral Leaders Taskforce and with the ACT Accelerator, the IMF stands ready to help countries meet the challenges of the pandemic and their financing needs—including through a Resilience and Sustainability Trust (RST).”

**Richard Hatchett, CEO, CEPI:**

“In many ways COVID-19 has shown us the potential of human ingenuity and innovation when we direct out energy and resources in fighting a common enemy. It has also tragically thrown into sharp focus a global failure to work multilaterally to ensure equal access to life saving vaccines.

“Vaccines are, and will continue to be, at the forefront of how modern societies counter infectious disease threats. They are one of our most potent tools against pandemic risks and will be critical to any future response. But if they are to truly fulfill their potential in preventing future pandemics their development must also go alongside investments in global surveillance, R&D, manufacturing, and health systems.
“During the course of this pandemic we have seen scientific advances that may well have taken decades to make in ‘peacetime’. Now, more than ever, the world now has the tools, the platforms, the concepts, and the experience to build a system that can more effectively meet the threat of future viruses.

“A future in which we are to respond to the next Disease X with new vaccines, therapeutics, and diagnostics in just 100 days is possible—but it will take vision, political will, and commensurate financial investments from governments around the world. We estimate that it will cost the world around $10 billion a year to ensure adequate global pandemic preparedness: this price tag is substantial, but failure to invest now—and build on the gains made in the response to COVID-19—will result in human and economic costs that will reverberate for generations.”

Peter Sands, Executive Director, Global Fund:
“The next phase of the fight against COVID-19 will be different. We are in for a long fight against a virus that continues to evolve. So we must shift to a more sustainable response that recognizes the linkages between responding to COVID-19, tackling the earlier pandemics of HIV, TB and malaria, and preparing for future pandemic threats. We should step up investment in systems for health, intentionally maximizing the synergies between interventions against existing infectious diseases and initiatives to prevent, detect and respond to future infectious disease outbreaks. Stronger and more resilient systems for health, including community systems, will enable us to protect everyone, everywhere from the deadliest infectious diseases.”

Jeremy Farrar, Director, Wellcome Trust:
“These last two years have shown that remarkable progress is possible when the world comes together and supports science boldly at scale, across borders. This approach gave us lifesaving Covid-19 vaccines and treatments in record time. Now is not the time to ease up – the virus’s next move is anything but certain and the risk of new variants high. We all desperately want this pandemic to be over. But simply wishing for the most optimistic scenario won’t make it so.

“We need to set our sights on developing next generation vaccines that can block transmission and won’t require endless boosters, strengthening genomic surveillance globally so we can identify and track new variants and improving global access to vaccines, treatments and tests. Leaving any countries unprotected, puts us all at risk.

“Most importantly, the response must be built on international co-operation. Only by working together can leaders achieve long-lasting and sustainable recovery from Covid-19 and prepare for the epidemic and pandemic threats of tomorrow.”

::::::

::::::

Ukraine

Emergency in Ukraine: external situation report #6, published 7 April 2022: reporting period: 31 March–6 April 2022
1.2 Access to health care in Ukraine

There are many challenges to accessing health care, with active hostilities and a lack of public transport restricting movement. Close to 1000 health facilities are in proximity to conflict areas or are in changed areas of control, multiple hospitals have been repurposed to care for wounds and half of the pharmacies in Ukraine have closed, which leaves the health system vulnerable to infrastructural damage and severe disruptions in critical services. As a consequence, there is limited or no access to medicines, health facilities, and health-care workers in some areas. Between 24 February and 6 April a total of 91 attacks on health care have been reported, resulting in 46 injuries and 73 deaths. Further attacks are being verified. Since 24 February 274 hospitals have been shelled, 13 have been completely destroyed, and 70 ambulances have been disabled by shelling...

Risk of emergence and spread of infectious diseases

Ongoing epidemics

The incidence of COVID-19 continues to decrease, with 14 120 new cases and 147 new deaths reported between 31 March and 5 April. However, these numbers should be interpreted carefully due to underreporting of COVID-19 cases and deaths. From 23 February to 6 April the seven-day average number of polymerase chain reaction tests and antigen-rapid diagnostic tests has declined significantly, with a 93% (from 42 460 to 1531) and 89% (from 51 484 to 6194) decrease, respectively. Vaccination uptake remains low, particularly in vulnerable populations, and the disruption in testing and treatment puts those most vulnerable at increased risk of severe illness and death.

Epidemic risk

:: Poor ventilation and overcrowding increase the risk of spread of respiratory infections, including COVID-19. Lack of access to water, sanitation and hygiene (WASH) heightens the risk of emergence of foodborne and waterborne diseases. According to United Nations Office for the Coordination of Humanitarian Affairs (OCHA), around six million people have either limited or no access to safe water, with active hostilities preventing repair teams from fixing damaged systems and restoring access to water while also hindering the delivery of water in the hardest-hit areas, like the Donetsk and Luhansk oblasts. Of note, an outbreak of cholera was reported in 2011 in the Mariupol region, while a single case was reported in 2016 in the Zaporizhzhya oblast, highlighting the risk of cholera outbreaks.

:: Suboptimal vaccination coverage for routine and childhood immunizations, including measles and poliomyelitis (polio), increases the risk of re-emergence and transmission of vaccine-preventable diseases. Notably, two cases of circulating vaccine-derived poliovirus type 2 (cVDPV2) were reported in Ukraine in 2021. On 1 February 2022 a national supplemental polio immunization campaign targeting nearly 140 000 children was launched, but due to the current situation it has been deprioritized and significantly slowed down.

:: With the arrival of spring and rising temperatures, disrupted access to WASH and damage to homes may increase the risk of vector-borne diseases such as West Nile fever and tick-borne encephalitis.
AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals

Deals mark an important step toward AMR Action Fund’s goal of bringing two to four new antibiotics to market to take on growing threat of drug-resistant bacteria

APRIL 4, 2022, BOSTON, MA – The AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antibiotics, announced today that it has invested in Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals. The transactions mark the Fund’s first investments and are an important step toward its goals of bringing to market new treatments for priority pathogens identified by the World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention.

“From inception, the AMR Action Fund has focused on identifying investments that will yield urgently needed treatments and catalyze long-term innovation to take on the growing threat of antimicrobial resistance (AMR), which now kills more people annually than HIV/AIDS or malaria,” said Bill Burns, Board Chair of the AMR Action Fund. “Welcoming Adaptive Phage Therapeutics and Venatorx Pharmaceuticals as our first portfolio companies demonstrates that we are well on our way to fulfilling this important mission.”

“Adaptive Phage Therapeutics and Venatorx Pharmaceuticals are poised to change the treatment landscape for drug-resistant infections and deliver significant benefit to patients,” said AMR Action Fund CEO, Henry Skinner. "While this is a major milestone for the Fund, our work is just beginning. We plan to commit over $100 million in capital this year in companies developing clinically differentiated antimicrobials with the potential to treat the most urgent unmet clinical needs, and we will continue investing in promising biotechs in the years ahead to ensure that patients around the world have the treatments they need in the ever-evolving fight against superbugs. Our investments are substantial, but we alone are not enough to take on the global challenge of AMR. It is now imperative that policymakers around the world enact market reforms to support investment in these urgently needed medications.”

APT’s approach leverages an ever-growing library of systematically discovered, selected, catalogued, and curated bacteriophages (phages), naturally occurring viruses that infect and kill bacteria, which collectively provide broad coverage against many of the world’s highest priority antibiotic-resistant bacteria. Phages from APT’s phage bank are matched to treat patients’ infections through a proprietary susceptibility assay, and are being tested on a range of infections, including prosthetic joint infections, bone infections (osteomyelitis), and lung infections. The AMR Action Fund’s investment in APT was executed as an extension to a Series B round led by Deerfield Management Company...
**IFPMA - Largest pharmaceutical industry-backed collective venture fund tackling antimicrobial resistance announces first portfolio investments**
April 4, 2022

---

**Coronavirus [COVID-19] - WHO**
*Public Health Emergency of International Concern (PHEIC)*
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

**Weekly Epidemiological and Operational updates**
Last update: 08 Apr 2022
**Confirmed cases:: **494 587 638
**Confirmed deaths:: **6 170 283
**Vaccine doses administered: **11 250 782 214

---

**Weekly epidemiological update on COVID-19 - 5 April 2022**

**Overview**
After the increase observed during the first half of March 2022, the number of new COVID-19 cases has decreased for a second consecutive week, with a 16% decline during the week of 28 March through 3 April 2022 as compared to the previous week.

The number of new weekly deaths also decreased sharply (-43%) as compared to the previous week, during which an artificial spike in deaths was observed.

Across the six WHO regions, over nine million new cases and over 26 000 new deaths were reported, and all the regions show decreasing trends both in the number of new weekly cases and new weekly deaths.

---

![COVID-19 cases reported weekly by WHO Region, and global deaths, as of 3 April 2022**](image-url)
As of 3 April 2022, just over 489 million cases and over 6 million deaths have been reported globally. In this edition, we provide an update on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the prevalence and summary of current evidence of the Omicron variant. We also provide updates on recombinants and vaccine effectiveness for the Delta and Omicron variants.

Over two-thirds of Africans exposed to virus which causes COVID-19: WHO study
07 April 2022
Brazzaville – Up to 65% of Africans have been infected by SARS-CoV-2, the virus which causes COVID-19, a World Health Organization (WHO) analysis finds. The study finds that true infections on the continent were 97 times larger than reported confirmed cases.

The analysis, which is available as a pre-print under peer review, synthesized 151 studies published on seroprevalence in Africa between January 2020 and December 2021. It found that exposure to SARS-CoV-2 skyrocketed from 3% (1.0–9.2% range) in June of 2020 to 65% (56.3–73% range) by September of 2021, or 800 million infections compared with 8.2 million cases reported at that time. The study showed that exposure to the virus rose sharply following the emergence of the Beta and the Delta variants.

The analysis revealed that the true number of infections could be as much as 97 times higher than the number of confirmed reported cases. This compares to the global average where true number of infections is 16 times higher than the number of confirmed reported cases.

However, seroprevalence varied widely within and across countries in Africa – higher in more dense urban areas than in less populated rural areas – and between age groups, with children aged 0–9 years having fewer infections compared with adults. Exposure to the virus also varied between countries and Africa’s sub-regions: seroprevalence appears to be highest in Eastern, Western and Central African regions.

The new analysis suggests that more than two-thirds of all Africans have been exposed to the COVID-19 virus. Globally seroprevalence studies have found a significant under-counting of cases occurring across the globe with 45.2% of the world’s population estimated to have been infected with the virus by September 2021. It is, however, difficult to compare figures for Africa with those of other regions, as many of the studies conducted cover different time periods.

The continent differentiates itself from other regions by its high number of asymptomatic cases, with 67% of cases having no symptoms.

“This analysis shows that current reported COVID-19 confirmed cases are only a fraction of the actual number of infections on the continent,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “This under-counting is occurring world-wide and it’s no surprise that the numbers are particularly large in Africa where there are so many cases with no symptoms.”...
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 March 2022

[New additions; Full scale view available at title link above]
[Updated on 09 Apr 2022]

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca
Press Releases - No new digest announcements identified
**Suspension of supply of COVID-19 vaccine (COVAXIN®)**

2 April 2022

Today, WHO confirmed the suspension of supply of Covaxin (Bharat Biotech) through UN procurement agencies, and recommended that countries using the vaccine take action as appropriate. The suspension is in response to the outcome of a WHO inspection on 14–22 March 2022, and the need to conduct process and facility upgrade to address recently identified deficiencies in good manufacturing practices (GMP).

Bharat Biotech has committed to addressing the GMP deficiencies and is developing a corrective and preventive action plan for submission to the Drugs Controller General of India (DCGI) and WHO. In the interim and as a precautionary measure, the company has indicated that it will suspend production of Covaxin for export. As a consequence, supply will be interrupted for the foreseeable future.

The risk assessment to date does not indicate change in the risk–benefit ratio. The data, available to WHO, indicate the vaccine is effective and no safety concerns exist...

**BE to Get mRNA Tech from WHO to Produce COVID-19 Vaccines**

**Biological E**

**News**

**WHO selects BE as a recipient of mRNA technology**

Biological E. Limited produces a number of critical & life-saving vaccines, including CORBEVAXTM

Hyderabad, April 4, 2022: Biological E. Limited (BE), one of the world’s largest vaccine manufacturers, has today announced that it has been selected as a recipient of mRNA technology from the World Health Organisation (WHO) technology transfer hub.

**BioNTech Granted Pandemic Preparedness Contract by German Federal Ministry of Health**

**Biontech**

**Press Releases**

MAINZ, Germany, April 8, 2022 — BioNTech SE (Nasdaq: BNTX) today announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the Federal Republic of Germany. The framework agreement is aimed at pandemic preparedness including manufacturing and supply of mRNA vaccines in emergency situations in Germany.

“There is growing evidence that viral pandemics will continue to pose a public health challenge for years. This contract with the German government will ensure significant supply of vaccine doses to address potential public health threats by 2027,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech...

**CanSinoBIO**

**News** - Website not responding at inquiry

**CIGB**

**Latest News** - No new digest announcements identified

**Cinagen**
**Recent News** - No new digest announcements identified

**Clover Biopharmaceuticals** - China
*News* - No new digest announcements identified

**Curevac [Bayer Ag – Germany]**
*News* - No new digest announcements identified

**Gamaleya National Center**
*Latest News and Events* - See Russia below.

**IMBCAMS**, China
*Home* - Website not responding at inquiry

**Janssen/JNJ**
*Press Releases*
Apr 04, 2022  United States
*World Health Organization Updated Emergency Use Listing Recommends Johnson & Johnson COVID-19 Vaccine for Booster Us*
:: WHO supports vaccine for use as same-dose and 'mix-and-match’ booster following a primary mRNA vaccine regimen
:: WHO also recommends extended shelf-life of up to 11 months for Johnson & Johnson COVID-19 vaccine when stored at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit)

**Medicago**
*Media* - No new digest announcements identified

**Moderna**
*Press Releases*
07 April, 2022
*IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies*

**Nanogen**
*News* - No new digest announcements identified

**Novavax**
*Press Releases*
*Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand*
Apr 8, 2022

**Pfizer**
*Recent Press Releases*
04.07.2022
*Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates*
:: Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus (RSV) infections and prevent illness through vaccination.
:: Expands Pfizer’s innovative anti-infective pipeline and utilizes the company’s R&D, manufacturing and commercialization expertise with the goal of addressing a significant unmet need for RSV treatments.

**R-Pharm**
https://rpharm-us.com/index.php
[No news or media page identified]

**Sanofi Pasteur**
*Press Releases* - No new digest announcements identified

**Serum Institute of India**
*NEWS & ANNOUNCEMENTS* - No new digest announcements identified

**Shifa Pharmed** [Iran]
http://shafapharmed.com/
No news page identified.

**Sinopharm/WIBPBIBP**
*News* - No new digest announcements identified

**Sinovac**
*Press Releases* - No new digest announcements identified

**Vector State Research Centre of Viralogy and Biotechnology**
*Home* - No new digest announcements identified

**WestVac Biopharma**
*Media* - No new digest announcements identified

**Zhifei Longcom**, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

:::

**GSK**
*Press releases for media* - No new digest announcements identified

**Merck**
*News releases*
*Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access*
April 04, 2022
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, reaffirmed its commitment to enable broad equitable access to the company’s HPV
vaccines. To support this, the company has invested significantly in manufacturing, and recently expanded its vaccines manufacturing facility located in Elkton, VA, completing the construction of 120,000 square feet and adding 150 new jobs at the site to further increase capacity and supply of the company’s human papillomavirus (HPV) vaccines, following regulatory reviews and approvals...

Novartis
News - No new digest announcements identified

SK Biosciences
Press releases -
SK bioscience Submits Post Approval Change Application of Protein-Based COVID-19 Vaccine for Adolescent Authorization to KMFDS
2022. 04. 07

Valneva
Press Releases - No new digest announcements identified

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 09 Apr 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.
The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 09 Apr 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability
Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID-19 Vaccine Roll-out

09 Apr 2022 | COVAX (WHO, GAVI, CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 494M total confirmed cases; 6.2M total confirmed deaths
Global vaccines administered: 11.4B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 280M
Other Delivered (Number of Doses): 260M
Total Delivered (Number of Doses): 540M
Total Administered (Number of Doses): 390M
https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 09 Apr 2022: https://data.covid19taskforce.com/data  The global view below is complemented by country-specific dashboards here.

Our World in Data
Coronavirus (COVID-19) Vaccinations  [Accessed 09 Apr 2022]
- 64.7% of the world population has received at least one dose of a COVID-19 vaccine.
- 11.37 billion doses have been administered globally, and 13.32 million are now administered each day.
- Only 14.8% of people in low-income countries have received at least one dose.
Remarks by HHS Secretary Becerra during a joint press conference on World Health Day with the World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus
April 7, 2022 | Speech

Remarks by Secretary Xavier Becerra at White House COVID-19 Briefing on New Federal Plan to Accelerate Support for People Experiencing Long-Term Effects of COVID-19
April 5, 2022 | Speech

BARDA – U.S. Department of HHS  [to 09 Apr 2022]
https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx
News
No new digest content identified.

FDA
Press Announcements
No new digest content identified.

Regulatory Actions
Final - March 31, 2022
Docket Number: FDA-2020-D-1137
Issued by: Center for Biologics Evaluation and Research
PDF: https://www.fda.gov/media/142749/download

FDA plays a critical role in protecting the United States (U.S.) from threats such as emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic.

FDA is issuing this guidance to provide sponsors of requests for Emergency Use Authorization (EUA) for COVID-19 vaccines with recommendations regarding the data and information needed to support the issuance of an EUA under section 564 of the FD&C Act (21 U.S.C. 360bbb-3) for an investigational vaccine to prevent COVID-19 for the duration of the COVID-19 public health emergency. This document supersedes the guidance of the same title issued in May 2021 (which superseded the guidance of the same title issued October 2020 and reissued February 2021).

Vaccines and Related Biological Products Advisory Committee- FDA
Vaccines and Related Biological Products Advisory Committee Meeting April 6, 2022

The committee met in open session to discuss considerations for use of COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants.

[No meeting materials posted as of 09 Apr 2022]

White House [U.S.]  [to 09 Apr 2022]

Statement by White House COVID-19 Response Coordinator Jeff Zients on American Lives Saved by the COVID-19 Vaccination Program
April 08, 2022 • Statements and Releases

A new study out today from the Commonwealth Fund shows that President Biden’s relentless efforts to get Americans vaccinated saved millions of American lives. Our vaccination campaign saved 2.2 million American lives, prevented 17 million hospitalizations, prevented 66 million COVID-19 cases, and avoided $900 billion in health care costs....

Statement from President Joe Biden for World Health Day 2022
April 07, 2022 • Statements and Releases

FACT SHEET: The Biden Administration’s Commitment to Global Health in the FY 2023 President’s Budget
April 07, 2022 • Statements and Releases

Press Briefing by White House COVID-19 Response Team and HHS Public Health Officials | April 5, 2022
April 05, 2022 • Press Briefings

Statement by Press Secretary Jen Psaki on COVID-19 Funding Proposal
April 05, 2022 • Statements and Releases

Memorandum on Addressing the Long-Term Effects of COVID-19
April 05, 2022 • Presidential Actions

FACT SHEET: The Biden Administration Accelerates Whole-of-Government Effort to Prevent, Detect, and Treat Long COVID
April 05, 2022 • Statements and Releases

U.S. Department of State  [to 09 Apr 2022]

Press Statement - COVID Context
No new digest content identified.
On the Urgent Need for Additional Global COVID-19 Resources
April 4, 2022
Statement by Administrator Samantha Power
Throughout the COVID-19 pandemic, Congress has consistently come together in an inspiring show of bipartisan support to fund our response. The $10 billion agreement announced this afternoon, while helping to fund our immediate domestic needs like treatments and tests, unfortunately leaves out the resources we need to power our global COVID response—an effort that is critical to preventing the emergence of new deadly variants and moving the world beyond this pandemic.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases
Press Releases
News: ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines (new)
Last updated: 06/04/2022
The European Centre for Disease Prevention and Control (ECDC) and EMA’s COVID-19 task force (ETF) have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines (Pfizer’s Comirnaty and Moderna’s Spikevax) in the general population.
However, both agencies agreed that a fourth dose (or second booster) can be given to adults 80 years of age and above after reviewing data on the higher risk of severe COVID-19 in this age group and the protection provided by a fourth dose.
ECDC and EMA also noted that there is currently no clear evidence in the EU that vaccine protection against severe disease is waning substantially in adults with normal immune systems aged 60 to 79 years and thus no clear evidence to support the immediate use of a fourth dose.
Authorities will continue to monitor data to determine if there is an increasing risk of severe illness among those who are vaccinated...

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates [Selected]
[No new digest content identified]
The "Stand Up for Ukraine" global pledging event and campaign has raised 9.1 billion euros for people fleeing the Russian invasion, inside Ukraine and abroad, including €1 billion from the European Commission.

The European Commission welcomes today's agreement by the Council to adopt a fifth package of restrictive measures against Putin's regime in response to its brutal aggression against Ukraine and its people.

With the aggravation of the food security and nutrition due to Russia's invasion of Ukraine, the EU is today reinforcing its political and financial commitment to partner countries in Africa. A total of €554 million in 2022 will be targeted at increasing food security in Sahel and Lake Chad.

---

https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Latest Updates [Selected]
[No new digest content identified]

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on: 09 April 2022, 08:00 IST (GMT+5:30)
(↑ Status change since yesterday)

Active (0.03%) 11365 (127↑)
Discharged (98.76%) 42501196 (1194↑)
Deaths (1.21%) 521656 (83↑)

Total Vaccination: 1,85,55,07,496 (14,79,544↑)
Government of India – Press Information Bureau

Latest Press Releases

COVID-19 Vaccination Update - Day 449
:: India's cumulative vaccination coverage crosses 185.68 Crore
:: More than 12 lakh Vaccine doses administered today till 7 pm
:: More than 2.21 Crore Vaccine Doses administered to 12-14 age group so far

Posted On: 09 APR 2022 8:14PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html

Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcements about Shanghai confirming the reports below; See China CDC below for additional announcements]

Shanghai widens COVID testing as other Chinese cities impose curbs
Reuters
April 8, 2022
- Most large Chinese cities keeping COVID restrictions in place
- Food supply issues persist in the locked-down city
- Senior epidemiologist calls for "thunderous" action to cut transmission

SHANGHAI, April 8 (Reuters) - Shanghai on Friday announced a record 21,000 new cases and a third consecutive day of COVID testing as a lockdown of its 26 million people showed no sign of easing and other Chinese cities tightened curbs - even in places with no recent infections.

Beijing authorities intervened in Shanghai after its failure to isolate COVID by locking the city down in stages, and insists that the country stick to its zero-tolerance policy to prevent its medical system from breaking down.

Authorities across China, which have mostly managed to keep COVID at bay for the last two years, are stepping up coronavirus control measures, including movement restrictions, mass testing and new quarantine centres.

Cities that sprang into action this week include Zhengzhou, in central Henan province, which on Thursday said it would test all 12.6 million residents after finding a few asymptomatic cases...

Many Shanghai residents say Covid lockdown measures have caused food shortages.
The authorities have locked down the city of 26 million in a bid to contain China's worst outbreak since the pandemic began.
New York Times, April 8, 2022
By Joy Dong
Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
https://polioeradication.org/polio-today/polio-now/this-week/

Polio this week as of 06 April 2022
:: The GPEI has released an updated draft version of the Standard Operating Procedures (SOPs) to offer guidance to any country that detects any type of poliovirus outbreak or event, to respond in a timely and effective manner. This version of the SOPs builds on the prior versions developed since 2015 and takes into account the key developments, lessons learnt and availability of new tools since :: This week, the Strategic Advisory Group of Experts on immunization (SAGE) is convening in Geneva, Switzerland. On polio eradication, the group will review the global current epidemiology, updated data
on novel oral polio vaccine type 2 (nOPV2) use, and recommendations on initial planning for OPV cessation.

:: On 26 April, the programme will launch the new investment case for the GPEI’s Strategy: Delivering on a Promise. This one-hour, virtual event, “Investing in the Promise of a Polio-free World”, will feature live remarks from WHO Director-General Dr Tedros Adhanom Ghebreyesus and UNICEF Executive Director Catherine Russell, as well as the stories of health workers and Ministers of Health working with the polio programme around the world. Please register here to learn more about the financial and political support needed to end polio for good.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
– DR Congo: seven cVDPV2 cases
– Egypt: one cVDPV2 positive environmental sample
– Nigeria: six cVDPV2 cases and seven positive environmental samples

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

7 April 2022 | Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia

Summary
This is the bi-annual update on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections reported to WHO from the Kingdom of Saudi Arabia. Between 1 August 2021 to 28 February 2022, six additional cases of MERS-CoV infections, including four associated deaths were reported to WHO from the Kingdom of Saudi Arabia. These cases were reported from Riyadh (four cases), Eastern (one case), and Taif (one case) regions. Based on the current situation and available information, WHO re-emphasizes the importance of strong surveillance by all Member States for acute respiratory infections, including MERS-CoV, and careful review of any unusual patterns.

WHO/OCHA Emergencies

Health emergencies list - WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

Afghanistan crisis [Last apparent update: 29 March 2022]
Crisis in Northern Ethiopia [Last apparent update: 1 June 2021]
Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 17 Aug 2021]
Coronavirus disease (COVID-19) pandemic  [See COVID above]

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020  
[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020  
[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018  
[Last apparent update: 24 July 2018]

Yemen crisis  
[Last apparent update: 12 February 2021]

Syria crisis  
[Last apparent update: 18 June 2021]

Somalia crisis  
[Last apparent update: 24 March 2018]

Nigeria crisis  
[Last apparent update: 1 Oct 2021]

Ebola outbreak, Democratic Republic of the Congo, 2017  
[Last apparent update: 17 Aug 2021]

Zika virus disease outbreak, 2015-2016  
[Last apparent update: 24 Jan 2020]

[Last apparent update: 17 Aug 2021]

Iraq crisis  
[Last apparent update: 9 Jan 2008]

South Sudan crisis  
[Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak  
[Last apparent update: 13 September 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak  
[Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic  
[Last apparent update: 10 Aug 2010]

--------

UN OCHA – Current Emergencies
Current Corporate Emergencies

Afghanistan
No new updates identified.

Northern Ethiopia
Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 7 Apr 2022

HIGHLIGHTS
- Only 8 per cent of cash needs transferred to Tigray for humanitarian operations since 12 July 2021.
- To date, about 15,000 people have been relocated to Sabacare 4 displacement site in Mekelle, reaching its full capacity.
- 245 schools in Afar remain closed, or 20 percent of the schools in the region, forcing more than 53,000 students out of school. Additional 5 schools are hosting displaced people.
- An additional 10 mobile health and nutrition teams were deployed to Amhara to scale-up the response, bringing the total number of teams operating in the region to 88.
- 30 mobile health and nutrition teams are operating in conflict affected areas in Afar, reaching more than 8,000 people with health care during the week.

**Ukraine**

**Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 8 April 2022)**

:::  
:::  

**WHO & Regional Offices** [to 09 Apr 2022]

[https://www.who.int/news](https://www.who.int/news)

**News** [Selected]

7 April 2022

*Departmental news*

**Open to all, anytime, anywhere: Free online courses bring vaccine knowledge to the global community**

6 April 2022

*News release*

**WHO urges accelerated action to protect human health and combat the climate crisis at a time of heightened conflict and fragility**

4 April 2022

*Departmental news*

**WHO announces updates on new TB antigen-based skin tests for the diagnosis of TB infection**

4 April 2022

*News release*

**Billions of people still breathe unhealthy air: new WHO data**

4 April 2022

*Departmental news*

**Health and the environment**

2 April 2022

*Departmental news*

**Suspension of supply of COVID-19 vaccine (COVAXIN®)**

Today, WHO confirmed the suspension of supply of Covaxin (Bharat Biotech) through UN procurement agencies, and recommended that countries using the vaccine take action as appropriate.
The suspension is in response to the outcome of a WHO inspection on 14–22 March 2022, and the need to conduct process and facility upgrade to address recently identified deficiencies in good manufacturing practices (GMP).

Bharat Biotech has committed to addressing the GMP deficiencies and is developing a corrective and preventive action plan for submission to the Drugs Controller General of India (DCGI) and WHO. In the interim and as a precautionary measure, the company has indicated that it will suspend production of Covaxin for export. As a consequence, supply will be interrupted for the foreseeable future.

The risk assessment to date does not indicate change in the risk–benefit ratio. The data, available to WHO, indicate the vaccine is effective and no safety concerns exist...

1 April 2022
Departmental news
Parliaments promote women’s, children’s and adolescents’ health in the time of COVID-19

:::

WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches
Selected
7 April 2022
Speech
WHO Director-General’s opening remarks at the World Health Day press briefing – 7 April 2022

:::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
:: 08 April 2022 Managing COVID-19 waste in Africa
:: 07 April 2022 Over two-thirds of Africans exposed to virus which causes COVID-19: WHO study
:: 06 April 2022 Africa faces rising climate-linked health emergencies
:: 01 April 2022 Major antibiotic donation moves African countries closer to defeating yaws

WHO Region of the Americas PAHO
:: On World Health Day, PAHO Director calls for concerted action to safeguard the health of the planet and its people
Washington, D.C., April 7, 2021 (PAHO) - After two years of the COVID-19 pandemic with millions of lives lost to the virus, Pan American Health Organization Director (PAHO) Carissa F. Etienne, marked World Health Day by calling for the urgent protection of the environment and highlighted how the health of the planet is linked to our own. “The so-

:: World Health Day 2022
World Health Day is celebrated every year on 7 April to commemorate the anniversary of the founding of the World Health Organization (WHO) in 1948. Each year for this date, a theme is chosen that highlights an area of priority concern for WHO. In the face of the current pandemic, a polluted planet, and an increasing incidence of diseases,

:: Americas at risk of further COVID-19 wave as cases surge in other regions, PAHO Director warns
Vaccination campaigns must focus on protecting the most vulnerable. Washington D.C. 6 April 2022 (PAHO) – As cases of COVID-19 surge in Europe and East Asia due to Omicron BA.2, the Pan American Health Organization (PAHO) Director Carissa F. Etienne has urged countries to remain vigilant and urgently close vaccination gaps. While COVID cases...

**WHO South-East Asia Region SEARO**
*No new digest content identified.*

**WHO European Region EURO**
:: [WHO records 100th attack on health care in Ukraine] 08-04-2022
:: [In solidarity with the health workers of Ukraine this World Health Day] 07-04-2022
:: [Ukraine: Crisis averted for now – WHO, PEPFAR and partners ensure supply of antiretroviral drugs for people living with HIV] 06-04-2022
:: [WHO Regional Director for Europe visits Kazakhstan, strengthens primary health care collaboration] 06-04-2022

**WHO Eastern Mediterranean Region EMRO**
*No new digest content identified.*

**WHO Western Pacific Region**
:: [7 April 2022 Countries in the Western Pacific on the frontlines of the climate crisis, says WHO] 07-04-2022
:: [7 April 2022 Regional Director’s remarks at the virtual press conference on 7 April 2022]

---

**WHO Events**

https://www.who.int/news-room/events/1

[Selected]

**Public hearings regarding a new international instrument on pandemic preparedness and response**
12 – 13 April 2022

In a consensus decision aimed at protecting the world from future infectious diseases crises, in December 2021 the World Health Assembly agreed to kickstart a global process by establishing an intergovernmental negotiating body (INB) to draft and negotiate a convention, agreement or other international instrument under the Constitution of the World Health Organization to strengthen pandemic prevention, preparedness and response.

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said the decision by the World Health Assembly was historic in nature, vital in its mission, and represented a once-in-a-generation opportunity to strengthen the global health architecture to protect and promote the well-being of all people.

As part of this historic decision, the World Health Assembly requested the Director-General to hold public hearings, in line with standard WHO practice, to support the work of the INB.

[Registration and additional information on the public hearings is available at https://inb.who.int](https://inb.who.int)
New WHO Publications
https://www.who.int/publications/i

Selected Titles
7 April 2022
Report of the first meeting of the WHO Technical Advisory Group on Diabetes: virtual meeting, 29-30 September...

7 April 2022
Emergency in Ukraine: external situation report #6, published 7 April 2022: reporting period: 31 March–6...

6 April 2022
Sharing and reuse of health-related data for research purposes: WHO policy and implementation guidance

Overview
The purpose of this document is to clarify the policy and practice on the reuse and onward sharing for research purposes of health data collected under the auspices of WHO technical programmes. This covers use in both emergency and non-emergency situations and complements the following: the Policy on use and sharing of data collected in Member States by the World Health Organization (WHO) outside the context of public health emergencies; the Policy statement on data sharing by the World Health Organization in the context of public health emergencies; and the Joint statement on public disclosure of results from clinical trials. This policy covers the reuse of health data for research purposes. Its scope includes research data generated by research undertaken directly by WHO, or funded by WHO, as well as the use of other health data for research purposes.

This document sets out the objectives of this WHO policy and the obligations of WHO staff and researchers funded by WHO. The following section of this document entitled Guidance on the implementation of the WHO policy on the sharing and reuse of health-related data for research purposes provides further references and resources to assist in the development of a data management and sharing plan that is in alignment with the vision of this policy.

6 April 2022
Clinical care of severe acute respiratory infections – Tool kit

6 April 2022
Strategic framework for collaboration on antimicrobial resistance

5 April 2022
Injection safety in the context of coronavirus disease (COVID-19) vaccination: Addendum to policy brief,...

4 April 2022
Stakeholder consultative meeting on prevention and management of childhood pneumonia and diarrhoea: report,...

4 April 2022
Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection

4 April 2022


WHO Drug Information - Volume 36, No. 1

3 April 2022
HIV module: Global competency and outcomes framework for universal health coverage

3 April 2022
Global competency framework for universal health coverage

3 April 2022
Global Competency and Outcomes Framework for Universal Health Coverage

1 April 2022
Compendium of WHO and other UN guidance on health and environment, 2022 update

CDC/ACIP [U.S.] [to 09 Apr 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements [Selected]
No new digest content identified.

ACIP Meetings
Next ACIP Meeting
April 20, 2022 11:00am – 4:00pm ET.
This meeting is virtual. No registration is required to watch the webcasts.
Webcast Link
No Agenda posted at inquiry

MMWR Weekly: Current Volume (71) April 8, 2022 / No. 14
PDF of this issue
- Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022
- Notes From the Field: SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous SARS-CoV-2 Delta Variant Infection — Four States, October 2021–January 2022

Coronavirus Disease 2019 (COVID-19)- CDC
Approximately 25 announcements/reports/data summaries.
:: 4/8/22 EARLY RELEASE: COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022
**Africa CDC** [to 09 Apr 2022]
http://www.africacdc.org/
*News*
*Fifteen “EPI-Biostat Fellows” commence Master’s training at the Kinshasa School of Public Health (KSPH)*
8 April 2022

**China CDC**
http://www.chinacdc.cn/en/

**National Health Commission of the People's Republic of China** [to 09 Apr 2022]
http://en.nhc.gov.cn/
*News*
*April 9: Daily briefing on novel coronavirus cases in China*
On April 8, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 1,350 new cases of confirmed infections.

**National Medical Products Administration – PRC** [to 09 Apr 2022]
http://english.nmpa.gov.cn/
*News*
*Chinese mainland reports 1,540 new local confirmed COVID-19 cases*
2022-04-08
The Chinese mainland reported 1,540 new locally-transmitted confirmed COVID-19 cases on April 7, the National Health Commission said on April 8.

*Nearly 2.79m more COVID-19 vaccine doses administered on Chinese mainland*
2022-04-08
The amount of COVID-19 vaccine doses administered on the Chinese mainland grew by around 2.79 million on Wednesday, with the total number exceeding 3.28 billion, data from the National Health Commission showed Thursday.

**CCDC Weekly Reports: Current Volume (4)**
2022-04-08 / No. 14  *COVID-19 ISSUE (25)*
View [PDF of this issue]
- Perspectives: The “Wolf” Is Indeed Coming: Recombinant “Deltacron” SARS-CoV-2 Detected
- Preplanned Studies: COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022
- **Preplanned Studies: Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants — China, May 21, 2021–February 28, 2022**
- **Preplanned Studies: Aerosol Transmission of SARS-CoV-2 in Two Dormitories — Hubei and Shandong Provinces, China, 2020**
- **Notes from the Field: A Local Cluster of Omicron Variant COVID-19 Likely Caused by Internationally Mailed Document — Beijing Municipality, China, January 2022**

::::::

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Emergencies
:: Organization Announcements
:: Journal Watch

::::::

**Organization Announcements**

Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Airfinity** [to 09 Apr 2022]
https://www.airfinity.com/insights

INSIGHTS & COMPANY NEWS
No new digest content identified.

**Paul G. Allen Frontiers Group** [to 09 Apr 2022]
https://alleninstitute.org/news-press/

News
No new digest content identified.

**BMGF - Gates Foundation** [to 09 Apr 2022]
https://www.gatesfoundation.org/ideas/media-center

Press Releases and Statements
No new digest content identified.

**Bill & Melinda Gates Medical Research Institute** [to 09 Apr 2022]
https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of
mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people.

No new digest content identified.

**CARB-X**  [to 09 Apr 2022]
https://carb-x.org/
News
No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation**  [to 09 Apr 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of *Vaccines and Global Health: The Week in Review* are available here.

:: **Informed Consent: A Monthly Review – April 2022** is now posted [here](https://centerforvaccineethicsandpolicy.net/News/Analysis/Statements/Reports/InformedConsentMonthlyReview/
:: **Statement on ICF [Informed Consent Form] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse**
:: **Patients, Politics, Pressure :: Pharma Stays Steady [Mostly] In Russia Sanctions Context Observations at 30 March 2022**  David R Curry

**CEPI – Coalition for Epidemic Preparedness Innovations**  [to 09 Apr 2022]
http://cepi.net/
Latest News
**CEPI partners with Japan’s NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine**
CEPI will provide funding of up to US$4.8m to support the programme - its first collaboration with Japanese industry.
08 Apr 2022

**CEPI invites vaccine developers and manufacturers to join global outbreak response network**
Existing vaccine facilities will work to develop, produce, store, and test vaccine candidates in response to new infectious disease outbreaks. CEPI is now inviting existing vaccine developers and production sites to express their interest in being part of the network.
07 Apr 2022

**CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants**
CEPI funding will support trial of UB-612 vaccine candidate as a 'mix-and-match' booster dose.
06 Apr 2022
EDCTP  [to 09 Apr 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
07 April 2022
Fifteen “EPI-Biostat Fellows” start their Master’s training at the Jomo Kenyatta University of Agriculture and Technology in Kenya
07 April 2022
Fifteen “EPI-Biostat Fellows” start their Master’s training at the Kinshasa School of Public Health in the Democratic Republic of Congo

Evidence Aid  [to 09 Apr 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
New Resources
No new digest content identified.
**Fondation Merieux**  [to 09 Apr 2022]  
http://www.fondation-merieux.org/  
*News, Events*  
*No new digest content identified.*

**Gavi**  [to 09 Apr 2022]  
https://www.gavi.org/  
*News Releases*  
8 April 2022  
**World leaders commit US$ 4.8 billion to help Break COVID Now**  
*[See COVID above for detail]*

7 April 2022  
**Nepal introduces Typhoid vaccine into routine immunisation across the country**  
:: The Ministry of Health and Population, Gavi, the Vaccine Alliance, UNICEF, WHO and other partners are collaborating on the nationwide typhoid vaccine introduction including a catch-up campaign, which seeks to vaccinate all children from the age of 15 months to 15 years to protect them from typhoid fever.  
:: The campaign aims to reach 95% coverage of nearly 7.5 million children with the typhoid conjugate vaccine (TCV) and simultaneously identify ‘zero-dose’ children and those that have missed other routine vaccines.

7 April 2022  
:: Gavi, MedAccess and the Open Society Foundations announce a new partnership to create an innovative Risk Sharing Facility to support the COVAX Cost-Sharing Mechanism.  
:: The partnership aims to build on intensive efforts by Gavi to extend its suite of innovative financing instruments to help donors and countries stretch their available resources as the pandemic shifts and to protect against future shocks. The Facility’s instruments also represent a pathway and toolkit to address future global health crises.  
:: This new partnership comes as Gavi seeks to raise additional funds to support COVAX. April 8 will see Germany, Indonesia and Senegal co-host the 2022 Gavi COVAX AMC Summit, where governments, international organisations, civil society and the private sector will come together to renew their commitment to global vaccination.

6 April 2022  
**Indonesia and Senegal to co-host 2022 Gavi COVAX AMC Summit, together with Germany**

**GHIT Fund**  [to 09 Apr 2022]  
https://www.ghitfund.org/newsroom/press  
*Press Releases*  
*No new digest content identified.*

**Global Fund**  [to 09 Apr 2022]
IAVI [to 09 Apr 2022]
https://www.iavi.org/
Latest News
IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies

Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis

NEW YORK, NY & CAMBRIDGE, MA — APRIL 7, 2022 — Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases — HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 — are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna’s mRNA platform and IAVI’s expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence....
The use of force in law enforcement operations

States often face situations in which their officials have to use force to maintain or restore public security, law and order in armed conflicts or situations of violence that do not meet the threshold of applicability of international humanitarian law.

What is international humanitarian law?

International humanitarian law (IHL) is a set of rules that seeks, for humanitarian reasons, to limit the effects of armed conflict.

International Coalition of Medicines Regulatory Authorities [ICMRA]


Selected Statements, Press Releases, Research

No new digest content identified.

IFFIm

http://www.iffim.org/

Press Releases/Announcements

IFFIm "essential" to continued financing for the COVAX AMC

05 Apr 2022

... IFFIm's established, in-demand vaccine bonds have already accelerated funding from donors to aid the fight against COVID-19. So far in this pandemic, over US$ 1.23 billion in new pledges have been committed to IFFIm for the COVAX AMC. IFFIm has frontloaded US$ 975 million raised on capital markets backed by those donations in 2021.

...By harnessing its frontloading capability, IFFIm can be a valuable financial tool helping Gavi and donors to respond as efficiently and effectively as possible to upcoming global health challenges without any immediate impact on donors' fiscal or official development assistance (ODA) positions.

"IFFIm has a crucial capability – bringing pledged money forward in time and putting it to work immediately. IFFIm was created 15 years ago to accelerate childhood vaccination, and was hugely successful at it. Now it's an essential part of funding the fight to break COVID," said Ken Lay, IFFIm Board Chair. "Working with Gavi and the World Bank, we expect it can do even more."

IFRC [to 09 Apr 2022]


Press Releases [Selected]

06/04/2022

People affected by crises everywhere deserve same strong support provided to Ukraine response

Geneva, 6 April 2022 - The International Federation of Red Cross and Red Crescent Societies (IFRC) calls for solidarity with people affected by crises everywhere as the response to the conflict in Ukraine shows the way.
The support from people and donors around the world demonstrates what is possible and illustrates the good practice essential in any humanitarian crisis. At the same time, the massive differences depending on where a crisis occurs and who it affects have been thrown into stark relief...

**Institut Pasteur** [to 09 Apr 2022]
*Press Documents*
*No new digest content identified.*

**IOM / International Organization for Migration** [to 09 Apr 2022]
*News - Selected*
*News*
08 Apr 2022
**15 Million People Face Humanitarian Crisis Due to Drought in the Horn of Africa**

*News*
05 Apr 2022
**7.1 Million People Displaced by the War in Ukraine: IOM Survey**

**ISC / International Science Council** [to 09 Apr 2022]
https://council.science/current/
*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*
*News Blogs Podcasts Events*
*No new digest content identified.*

**IVAC** [to 09 Apr 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
*Updates; Events*
**World Immunization Week 2022: Webinars**
April 2022
During World Immunization Week 2022 the International Vaccine Access Center, along with global immunization and indigenous health partners, will host a three webinars. Registration is free, and we encourage all to sign up and save these dates on their calendars. Enabling Equitable Access to COVID-19 Vaccines for Indigenous Populations When: April 26, 2022 from 6:00 […]

**IVI** [to 09 Apr 2022]
http://www.ivi.int/
*IVI News & Announcements*
*No new digest content identified.*
Johns Hopkins Center for Health Security  [to 09 Apr 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Centers News
Johns Hopkins Center for Health Security Co-Hosts United States–India Strategic Dialogue on Biosecurity to Discuss Lessons from the Second Year of National Pandemic Responses
April 7, 2022
Report from the Eighth Dialogue Session, Focused on the Second Year of COVID-19 Responses in India and the United States and the Pandemic’s Impact on Global Biosecurity (PDF)

MSF/Médecins Sans Frontières  [to 09 Apr 2022]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

National Academy of Medicine - USA  [to 09 Apr 2022]
https://nam.edu/programs/
News
No new digest content identified.

National Academy of Sciences - USA  [to 09 Apr 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS  [to 09 Apr 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH  [to 09 Apr 2022]
News Releases
No new digest content identified.

OECD  [to 09 Apr 2022]
http://www.oecd.org/newsroom/publicationsdocuments/bydate/
Newsroom/Library
No new digest content identified.

PATH  [to 09 Apr 2022]
Sabin Vaccine Institute  [to 09 Apr 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS  [to 09 Apr 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
7 April 2022
New framework for action for male engagement in the HIV response in eastern and southern Africa launched

7 April 2022
Urgently needed HIV services are supporting Ukrainian refugees in the Republic of Moldova

6 April 2022
United Kingdom parliamentary group visits UNAIDS to strengthen collaboration

6 April 2022
Young people’s monitoring of progress towards 2025 targets begins second phase

UNHCR Office of the United Nations High Commissioner for Refugees [to 09 Apr 2022]
Selected News Releases, Announcements
UNHCR redoubles its aid inside Ukraine and the region
This is a summary of what was said by UNHCR spokesperson Matthew Saltmarsh – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva.
08 April 2022

UNICEF  [to 09 Apr 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements  [Selected]
Press release
04/07/2022
As the war in Ukraine continues, millions of children in the Middle East and North Africa at increased risk of malnutrition amid food price hikes
AMMAN, 7 April 2022- Six weeks into the war in Ukraine, the fragile nutritional status of children in the Middle East and North Africa is expected to worsen. While Muslims in the region observe the holy month of Ramadan, disruption in imports caused by the conflict is creating food shortages amid high prices of essential commodities, including...

Unitaid [to 09 Apr 2022]
https://unitaid.org/
Featured News
07 April 2022
On World Health Day, Unitaid rallies around the “Our Planet, our Health” campaign
  Geneva – Unitaid joins partners to observe World Health Day 2022 today, reaffirming its strong commitment to contribute to keep humans and the planet healthy.
  Climate change has been identified as the single biggest health threat of the 21st century, already harming the world’s most vulnerable people and menacing to undermine decades of progress in global health...

Vaccine Equity Cooperative [nee Initiative] [to 09 Apr 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 09 Apr 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 09 Apr 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 09 Apr 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 09 Apr 2022]
https://wellcome.ac.uk/news
News, Opinion, Reports
No new digest content identified.
**The Wistar Institute** [to 09 Apr 2022]
*Press Releases*
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 09 Apr 2022]
https://www.wfpha.org/
*Latest News - Blog*
*No new digest content identified.*

**World Bank** [to 09 Apr 2022]
*Selected News, Announcements*
**Remarks by Mamta Murthi, Vice President for Human Development at the Gavi COVAX AMC**
*"Break COVID Now" Summit*
*Date: April 08, 2022 Type: Statement*

**World Customs Organization – WCO** [to 09 Apr 2022]
http://www.wcoomd.org/
*Latest News*
*08 April 2022*
**Ethics and Transparency: A commitment for all**
With the aim of exchanging best practices and motivating Customs Administrations to promote ethics through WCO tools, the Webinar "Ethics and Transparency - A Commitment for All" was organized by the Private Sector Consultative Group and the WCO Regional Vice-Chair for the Americas and the Caribbean...

**World Organisation for Animal Health (OIE)** [to 09 Apr 2022]
https://www.oie.int/en/media/news/
*Press Releases, Statements*
**Acting for better aquatic animal health and welfare worldwide**
*3 April 2022  France, Paris*
The World Organisation for Animal Health (OIE) joins the World Aquatic Animal Day celebrations by raising awareness on the need to maintain sustainable aquatic ecosystems to ensure a better future for all.
Over 50 million people worldwide depend on fisheries and aquaculture for their livelihoods. However, aquatic animal diseases can jeopardise the economic and environmental sustainability of this source of income. For instance, on a global scale, disease outbreaks cost the aquaculture industry over US$6 billion per year...

**WTO - World Trade Organisation** [to 09 Apr 2022]
http://www.wto.org/english/news_e/news_e.htm
*WTO News and Events [Selected]*
Members welcome COVID-19 trade-related measures report, agree on future experience sharing
31 March 2022

Members welcomed the latest update on export restrictions and prohibitions and trade-easing measures relating to the COVID-19 pandemic, which was presented by the WTO Secretariat at a meeting of the Committee on Market Access on 30-31 March. The Committee also heard about the first experience-sharing session on COVID-19-related goods, where members sought to better understand how they define lists of “essential goods” to combat the pandemic and the challenges they face with tariff classification.

DDG Ellard: WTO is essential to the rules-based international order
31 March 2022

In her address to the Steering Committee of the Inter-Parliamentary Union on 31 March, Deputy Director-General Angela Ellard provided an overview of the state of negotiations in the run-up to the 12th Ministerial Conference (MC12). She also highlighted the importance of the rules based international order and multilateralism, particularly in light of the war in Ukraine, and called on parliamentarians to help “make the world safer and more prosperous through trade”. The full text of her remarks is below.

:::::::

ARM [Alliance for Regenerative Medicine] [to 09 Apr 2022]
Selected Press Releases
No new digest content identified.

BIO [to 09 Apr 2022]
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 09 Apr 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 09 Apr 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 09 Apr 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Largest pharmaceutical industry-backed collective venture fund tackling antimicrobial resistance announces first portfolio investments

April 4, 2022, Geneva – The international trade body representing the biopharmaceutical industry (IFPMA) today welcomes the announcement of the AMR Action Fund’s first portfolio investments. The Fund is the world’s largest public-private partnership investing in biotech companies that are developing antibiotics, involving more than 20 leading biopharmaceutical companies who raised the majority of the approximately US $1 billion when the Fund was launched in 2020. IFPMA played an instrumental role conceiving the Fund in collaboration with the European Investment Bank, the Wellcome Trust and the World Health Organization.

The announcement marks an important milestone for the Fund, which has as its goal to invest in the development of between two and four new antibiotics by 2030. New antibiotics are critical to helping stem the rise of antimicrobial resistance (AMR), which is a leading cause of death worldwide. At least 1.27 million deaths per year are directly attributable to infections that have grown resistant to existing antibiotics, with an additional 4.95 million deaths associated with resistant infections...

[See AMR Action Fund announcements in Perspectives above]

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO  [to 09 Apr 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

PhRMA  [to 09 Apr 2022]
http://www.phrma.org/
Latest News [Selected]
No new digest content identified.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Emergencies
:: Organization Announcements
:: Journal Watch

* * * * *
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 4: E249-341 Apr 2022
https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities

Health Equity in US Latinx Communities
Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

American Journal of Infection Control
April 2022 Volume 50 Issue 4 p367-476
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
April 2022 Volume 62 Issue 4 p473-660
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
April 2022 112(52)
http://ajph.aphapublications.org/toc/ajph/current

Supplement 2 2022 = Global Opioid Crisis
American Journal of Tropical Medicine and Hygiene
Volume 106 (2022): Issue 2 (Feb 2022)
https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml
[Reviewed earlier]

Annals of Internal Medicine
March 2022 Volume 175, Issue 3
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 305 April 2022
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 09 Apr 2022)
[No new digest content identified]

BMJ Global Health
April 2022 - Volume 7 - 4
https://gh.bmj.com/content/7/4
Analysis
Ethical considerations in international clinical trial site selection (6 April, 2022)
Jennifer Miller, Joseph Millum
Abstract
New medicines and vaccines are predominantly tested in high-income countries. However, as the COVID-19 pandemic highlighted, the populations who can benefit from these interventions are not limited to these wealthier regions. One-third of novel Food and Drug Administration approved drugs, sponsored by large companies, treat infectious diseases like tuberculosis and HIV, which disproportionately affect low-income and middle-income countries (LMICs). The medicines for non-communicable diseases (NCDs) are also relevant to LMIC health needs, as over three-quarters of deaths from NCDs occur in LMICs. There are concerns clinical trial data may not extrapolate across geographical regions, as product effectiveness can vary substantially by region. The pentavalent rotavirus vaccine, for example, had markedly lower efficacy in LMICs. Efficacy variations have also been found for other vaccines and drugs. We argue there are strong ethical arguments forremedying some of this uneven distribution of clinical trial sites by geography and income. Chief among them, is that these disparities can impede equitable access to the benefits of clinical research, such as representation in the evidence base generated to guide prescribing and use of medicines and vaccines. We suggest trial site locations should be made more transparent and for later stage trials their selection should be informed by the global distribution of disease burden targeted by an experimental product. Countries with high prevalence, incidence, severity or infection transmission rates for targeted
diseases should have real opportunities to engage in and enrol their populations in trials for novel medicines and vaccines.

**BMC Health Services Research**
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 09 Apr 2022)

**Examining the unit costs of COVID-19 vaccine delivery in Kenya**
Vaccines are considered the path out of the COVID-19 pandemic. The government of Kenya is implementing a phased strategy to vaccinate the Kenyan population, initially targeting populations at high risk of seve...

Authors: Stacey Orangi, Angela Kairu, Anthony Ngatia, John Ojal and Edwine Barasa
Citation: BMC Health Services Research 2022 22:439
Content type: Research Published on: 4 April 2022

**BMC Infectious Diseases**
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 09 Apr 2022)

[No new digest content identified]

**BMC Medical Ethics**
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 09 Apr 2022)

**Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States**

HIV cure research involving cell and gene therapy has intensified in recent years. There is a growing need to identify ethical standards and safeguards to ensure cell and gene therapy (CGT) HIV cure research r...

Authors: Karine Dubé, John Kanazawa, Hursch Patel, Michael Louella, Laurie Sylla, Jeff Sheehy, Lynda Dee, Jeff Taylor, Jen Adair, Kim Anthony-Gonda, Boro Dropulić, John A. Sauced, Michael J. Peluso, Steven G. Deeks and Jane Simoni
Citation: BMC Medical Ethics 2022 23:39
Content type: Research Published on: 9 April 2022

**BMC Medicine**
http://www.biomedcentral.com/bmcmed/content
(Accessed 09 Apr 2022)

**CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study**

More doses of CoronaVac have been administered worldwide than any other COVID-19 vaccine. However, the effectiveness of COVID-19 inactivated vaccines in pregnant women is still unknown. We estimated the vaccin...

Authors: Enny S. Paixao, Kerry L. M. Wong, Flavia Jôse Oliveira Alves, Vinicius de Araújo Oliveira, Thiago Cerqueira-Silva, Juracy Bertoldo Júnior, Tales Mota Machado, Elzo Pereira Pinto Junior, Viviane
Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study

Hundreds of millions of doses of coronavirus disease 2019 (COVID-19) vaccines have been administered globally, but progress on vaccination varies considerably between countries. We aimed to provide an overall picture of COVID-19 vaccination campaigns, including policy, coverage, and demand of COVID-19 vaccines.

Authors: Zhiyuan Chen, Wen Zheng, Qianhui Wu, Xinghui Chen, Cheng Peng, Yuyang Tian, Ruijia Sun, Jiayi Dong, Minghan Wang, Xiaoyu Zhou, Zeyao Zhao, Guangjie Zhong, Xuemei Yan, Nuolan Liu, Feiran Hao, Sihong Zhao...

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content

[No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles

“Most of the cases are very similar.”: Documenting and corroborating conflict-related sexual violence affecting Rohingya refugees

In August 2017, a large population of Rohingya from northern Rakhine state in Myanmar fled to Bangladesh due to “clearance operations” by the Myanmar security forces characterized by widespread and systematic ...

Authors: Lindsey Green, Thomas McHale, Ranit Mishori, Linda Kaljee and Shahanoor Akter Chowdhury

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content

Factors associated with COVID-19 vaccine intent among Latino SNAP participants in Southern California

COVID-19 is significantly impacting the health and well-being of the country, particularly for ethnic minority populations and low-income groups. Our goal was to determine COVID-19 vaccination intent in a low-...

Authors: Vanessa P. Scott, Sarah Hiller-Venegas, Kate Edra, Joe Prickitt, Yesenia Esquivel, Blanca Melendez and Kyung E. Rhee
Reimagining peer review as an expert elicitation process

Journal peer review regulates the flow of ideas through an academic discipline and thus has the power to shape what a research community knows, actively investigates, and recommends to policymakers and the wid...

Authors: Alexandru Marcoci, Ans Vercammen, Martin Bush, Daniel G. Hamilton, Anca Hanea, Victoria Hemming, Bonnie C. Wintle, Mark Burgman and Fiona Fidler
Citation: BMC Research Notes 2022 15:127
Content type: Commentary Published on: 5 April 2022

BMJ Evidence-Based Medicine
April 2022 - Volume 27 - 2
https://ebm.bmj.com/content/27/2
[Reviewed earlier]

BMJ Open
April 2022 - Volume 12 - 4
https://bmjopen.bmj.com/content/12/4

Original research: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults (8 April, 2022)

Original research: Vaccination coverage among COVID-19 prevention and control management teams at primary healthcare facilities in China and their attitudes towards COVID-19 vaccine: a cross-sectional online survey (7 April, 2022)
Yun-Yun Yan, Hai-Tang Wang, Teng-Yang Fan, Xian-Jin Sun, Zhao-Hui Du, Xiao-Ming Sun

Original research: Understanding national trends in COVID-19 vaccine hesitancy in Canada: results from five sequential cross-sectional representative surveys spanning April 2020–March 2021 (5 April, 2022)
Kim Lavoie, Vincent Gosselin-Boucher, Jovana Stojanovic, Samir Gupta, Myriam Gagné, Keven Joyal-Desmarais, Katherine Séguin, Sherri Sheinfeld Gorin, Paula Ribeiro, Brigitte Voisard, Michael Vallis, Kimberly Corace, Justin Presseau, Simon Bacon

Protocol: Using human-centred design to tackle COVID-19 vaccine hesitancy for children and youth: a protocol for a mixed-methods study in Montreal, Canada (5 April, 2022)
Britt McKinnon, Krystelle Abalovi, Ashley Vandermorris, Ève Dubé, Cat Tuong Nguyen, Niels Billou, Geneviève Fortin, Maryam Parvez, Joyeuse Senga, Joe Abou-malhab, Medjine Antoine Bellamy, Caroline Quach, Kate Zinszer

Original research: How did the adoption of wP-pentavalent affect the global paediatric vaccine coverage rate? A multicountry panel data analysis (4 April, 2022)
Editorials

**Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032**
Lisa L Carter, M Anne Yu, Jilian A Sacks, Céline Barnadas, Dmitriy Pereyaslov, Sébastien Cognat, Sylvie Briand, Michael J Ryan, Gina Samaan
Bull World Health Organ. 2022 Apr 1; 100(4): 239–239A. Published online 2022 Apr 1.
doi: 10.2471/BLT.22.288220
PMCID: PMC8958828

**WHO recommendations for resilient health systems**
Tedros Adhanom Ghebreyesus, Zsuzsanna Jakab, Michael J Ryan, Jaouad Mahjour, Suraya Dalil, Stella Chungong, Gerard Schmets, Geraldine Mcdarby, Redda Seifeldin, Sohel Saikat
Bull World Health Organ. 2022 Apr 1; 100(4): 240–240A. Published online 2022 Apr 1.
doi: 10.2471/BLT.22.287843
PMCID: PMC8958831

Research

**Expansion of the measles and rubella laboratory network, India**
Bull World Health Organ. 2022 Apr 1; 100(4): 247–255. Published online 2022 Feb 3.
doi: 10.2471/BLT.21.286999
PMCID: PMC8958835

**Screening for Hepatitis B in partners and children of women positive for surface antigen, Burkina Faso**
Alice Nanellin Guingané, Rémi Kaboré, Yusuke Shimakawa, Eric Nagaonlé Somé, Dramane Kania, Amandine Pisoni, Nicolas Nagot, Rachel King, Roger Sombié, Nicolas Meda, Philippe Van de Perre, Edouard Tuaillon
Bull World Health Organ. 2022 Apr 1; 100(4): 256–267. Published online 2022 Feb 22.
doi: 10.2471/BLT.21.287015
PMCID: PMC8958837

Policy & Practice

**Protecting noncommunicable disease prevention policy in trade and investment agreements**
Therapeutic Innovations in Neuroscience

The theme of this issue of Clinical Pharmacology & Therapeutics (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

Clinical Trials
Volume 19 Issue 1, February 2022
https://journals.sagepub.com/toc/ctja/19/1
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 09 Apr 2022]
Gender-based violence experiences among Palestinian women during the COVID-19 pandemic: mental health professionals’ perceptions and concerns
Authors: Fayez Mahamid, Guido Veronese and Dana Bdier
Content type: Research 4 April 2022

Contemporary Clinical Trials
Volume 114  March 2022
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 1 / February 2022
https://www.liebertpub.com/toc/crispr/5/1
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2022 - Volume 35 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 1  Pages: 1-62  March 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 1, 2021
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]
Disaster Medicine and Public Health Preparedness
Volume 15 - Issue 6 - December 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 46, Issue 2 Pages: 299-586 April 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23 Issue 4 5 April 2022
https://www.embopress.org/toc/14693178/current
Opinion 15 March 2022 Free Access
Science in times of war: oppose Russian aggression but support Russian scientists
Eugene V Koonin
In the face of Russia’s invasion of the Ukraine, the global scientific community must continue to support their Russian colleagues without endorsing their government.
Science & Society 23 February 2022 Open Access

Lamarck redux and other false arguments against SARS-CoV-2 vaccination: Pseudoscientific arguments against vaccination do not stand up to scrutiny
Emanuel Goldman
The COVID-19 pandemic has triggered a new bout of anti-vaccination propaganda. These are often grounded in pseudoscience and misinterpretation of evolutionary biology.

Emerging Infectious Diseases
Volume 28, Number 4—April 2022
http://wwwnc.cdc.gov/eid/
Expedited Articles
Recombinant BA.1/BA.2 SARS-CoV-2 Virus in Arriving Travelers, Hong Kong, February 2022
H. Gu et al.

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Glatman-Freedman et al.

Synopses
M. Talaat et al.
Epidemics
Volume 38  March 2022
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 2  Pages: 1-40  March–April 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Consent and decisional capacity; Outside experts and IRBs; Therapeutic misconception
[Reviewed earlier]

Ethics & International Affairs
Winter 2021 (35.4)  December 2021
https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/
TABLE OF CONTENTS
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 20  February 2022
[Reviewed earlier]

The European Journal of Public Health
Volume 32, Issue 2, April 2022
https://academic.oup.com/eurpub/issue/32/2
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (4) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]
**Genome Medicine**  
https://genomemedicine.biomedcentral.com/articles  
[Accessed 09 Apr 2022]  
[No new digest content identified]

**Global Health Action**  
Volume 15, Issue 1 (2022)  
https://www.tandfonline.com/toc/zgha20/current?nav=tocList  
[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**  
Vol. 10, No. 1  February 28, 2022  
http://www.ghspjournal.org/content/current  
[Reviewed earlier]

**Global Legal Monitor – Library of Congress/USA**  
https://www.loc.gov/collections/global-legal-monitor/  
[Accessed 09 Apr 2022]  
[No new digest content identified]

**Global Public Health**  
Volume 17, Issue 4 (2022)  
http://www.tandfonline.com/toc/rgph20/current  
[Reviewed earlier]

**Globalization and Health**  
http://www.globalizationandhealth.com/  
[Accessed 09 Apr 2022]  
[No new digest content identified]

**Health and Human Rights**  
Volume 23, Issue 2, December 2021  
https://www.hhrjournal.org/volume-23-issue-2-december-2021/  
[Reviewed earlier]

**Health Economics, Policy and Law**  
Volume 17 - Issue 2 - April 2022  
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue  
[Reviewed earlier]
Health Policy and Planning
Volume 37, Issue 3, March 2022
https://academic.oup.com/heapol/issue/37/3
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 09 Apr 2022]
[No new digest content identified]

Human Gene Therapy
Volume 33, Issue 5-6 / March 2022
https://www.liebertpub.com/toc/hum/33/5-6
[Reviewed earlier]

Humanitarian Practice Network
https://odihrmn.org/
Online Article
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 1, 2022
https://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

Immunity
Mar 08, 2022 Volume 55 Issue 3 p377-574
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 09 Apr 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 09 Apr 2022]
[No new digest content identified]
JAMA
April 5, 2022, Vol 327, No. 13, Pages 1209-1300
https://jamanetwork.com/journals/jama/currentissue

Original Investigation
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19A Randomized Clinical Trial
Anil Gupta, MD; Yaneicy Gonzalez-Rojas, MD; Erick Juarez, MD; et al.
free access has active quiz
This randomized clinical trial compares the efficacy and adverse events of sotrovimab vs placebo in preventing progression of mild to moderate COVID-19 to severe disease.

Caring for the Critically Ill Patient
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19A Randomized Clinical Trial
This randomized clinical trial assesses the effect of treatment with an antiplatelet agent vs no antiplatelet therapy on days alive and free of intensive care unit respiratory or cardiovascular organ support within 21 days among patients critically ill with COVID-19.

Editorial

**Thromboinflammation and Antithrombotics in COVID-19**

Accumulating Evidence and Current Status

Jean M. Connors, MD; Paul M Ridker, MD, MPH

**Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction**

Katia Bruxvoort, PhD; Jeff Slezak, MS; Lei Qian, PhD; et al.

This large prospective cohort study compares the rates of acute myocardial infarction between recipients of a 2-dose hepatitis B vaccine and recipients of a 3-dose hepatitis B vaccine.

**Research Letter**

**Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada**

Ana Cecilia Ulloa, MPH; Sarah A. Buchan, PhD; Nick Daneman, MD, MSc; et al.

This study examines hospitalizations and deaths associated with the SARS-CoV-2 Omicron variant compared with matched patients infected with the Delta variant.

**Viewpoint**

**Expanding Efforts and Support to Respond to the HIV and COVID-19 Intersecting Pandemics**

Lawrence Corey, MD; Russell Corbett-Detig, PhD; Chris Beyrer, MD, MPH

This Viewpoint discusses the generation of SARS-CoV-2 variants of concern globally and the need for increased access to COVID-19 vaccination in Africa, particularly for people living with HIV and for households and people living in densely populated communities.

**JAMA Network**

**COVID-19 Update April 9, 2022**

These articles on COVID-19 were published across the JAMA Network in the last week.

**JAMA Pediatrics**

April 2022, Vol 176, No. 4, Pages 335-428

https://jamanetwork.com/journals/jamapediatrics/currentissue

[New issue; No digest content identified]
JBI Evidence Synthesis
March 2022 - Volume 20 - Issue 3
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
April 2022 Volume 70 Issue 4 p517-696
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 73 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 2, April 2022
[Reviewed earlier]

Journal of Development Economics
Volume 156 May 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 1-2, February-April 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
March 2022 - Volume 76 - 3
https://jech.bmj.com/content/76/3
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 14, Issue 4 Pages: 257-345 December 2021
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]
Journal of Global Ethics
Volume 17, Issue 3, 2021
http://www.tandfonline.com/toc/rijge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 1, February 2022
https://muse.jhu.edu/issue/47329
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 2, April 2022
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 20, 2022 , Issue 1
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 225, Issue 3, 1 February 2022
https://academic.oup.com/jid/issue/225/3
[Reviewed earlier]

Journal of Medical Ethics
April 2022 - Volume 48 - 4
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 1 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
April 2022 Volume 243 p1-246
http://www.jpeds.com/current
Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 09 Apr 2022]
[No new digest content identified]

Journal of Public Health Management & Practice
May/June 2022 - Volume 28 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Public Health Policy
Volume 43, issue 1, March 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-1
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
April 2022  Volume 19  Issue 189
https://royalsocietypublishing.org/toc/rsif/current
[New issue; No digest content identified]

Journal of Travel Medicine
Volume 29, Issue 2, March 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96  Number 4  February 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Apr 09, 2022  Volume 399  Number 10333  p1359-1440, e32-e36
https://www.thelancet.com/journals/lancet/issue/current
Seminar
Cholera
Suman Kanungo, Andrew S Azman, Thandavarayan Ramamurthy, Jaqueline Deen, Shanta Dutta

The Lancet Child & Adolescent Health
Apr 2022 Volume 6 Number 4 p215-278, e13-e15
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Apr 2022 Volume 4 Number 4 e207-e289
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Apr 2022 Volume 10 Number 4 e448-e584
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Apr 2022 Volume 22 Number 4p 427-562, e101-e127
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Apr 2022 Volume 7 Number 4 e291-e390
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Apr 2022 Volume 10 Number 4 p313-420, e34-e43
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 26, issue 3, March 2022
[Reviewed earlier]

Medical Decision Making (MDM)
Evidence from a statewide vaccination RCT shows the limits of nudges
Nathaniel Rabb, Megan Swindal, David Yokum
**Nature Reviews Genetics**

Volume 23 Issue 4, April 2022  
https://www.nature.com/nrg/volumes/23/issues/4  
Review Article | 02 December 2021

**The potential of mitochondrial genome engineering**
  
The authors review the field of mammalian mitochondrial genome engineering, culminating in the recent development of mitochondrially targeted programmable nucleases and base editors. They describe research that led to the development of animal models of mitochondrial disease, as well as the potential for translating these approaches to the clinic.  
Pedro Silva-Pinheiro, Michal Minczuk

**Perspective | 10 November 2021**

**Functional genomics data: privacy risk assessment and technological mitigation**
  
This Perspective highlights privacy issues related to the sharing of functional genomics data, including genotype and phenotype information leakage from different functional genomics data types and their summarization steps. The authors also review the techniques that will enable broad sharing and analysis while maintaining privacy.  
Gamze Gürsoy, Tianxiao Li, Mark B. Gerstein

**Nature Reviews Immunology**

Volume 22 Issue 4, April 2022  
https://www.nature.com/nri/volumes/22/issues/4  
Comment | 15 February 2022

**Lessons from Long COVID: working with patients to design better research**
  
In this Comment article, Nisreen Alwan discusses what her experience as both a public health academic and a person living with Long COVID has taught her about the importance of including those with lived experience of a condition in setting the research agenda.  
Nisreen A. Alwan

Collection: COVID-19 Watch  
Comment | 23 February 2022

**Vaccine safety in an era of novel vaccines: a proposed research agenda**
  
In this Comment article, Gregory Poland and Richard Kennedy outline the importance of continued funding and infrastructure support for research into vaccine safety to inform public health decisions and increase public trust in new vaccine technologies.  
Gregory A. Poland  
Richard B. Kennedy

Review Article | 26 July 2021

**Mucosal vaccines — fortifying the frontiers**
  
Here, Ed Lavelle and Ross Ward discuss the unique aspects of mucosal immunity that must be considered when developing effective mucosal vaccines. The authors highlight the key immune cell populations that are targeted by mucosal vaccination strategies and explain how innovative adjuvant and delivery approaches should lead to new vaccines for infectious diseases and cancers.  
Ed C. Lavelle
Identification of neoantigens for individualized therapeutic cancer vaccines

Mutations in cancer cells can generate tumour-specific neoepitopes, which are attractive targets for anticancer vaccines. This Review discusses the mechanisms of neoantigen T cell recognition and computational approaches to predict which neoantigens might confer proficient antitumour immunity in a given clinical context.
Franziska Lang, Barbara Schrörs, Ugur Sahin

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa

Widespread underlying SARS-CoV-2 seropositivity was observed in Gauteng before the omicron-dominant wave of Covid-19. Epidemiologic data showed a decoupling of hospitalizations and deaths from infections while omicron was circulating.

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

Janying Liu, et al.

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

Janying Liu, et al.
PLOS Biology
https://journals.plos.org/plosbiology/
(Accessed 09 Apr 2022)
[No new digest content identified]

PLOS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 09 Apr 2022)
[No new digest content identified]

PLOS Medicine
http://www.plosmedicine.org/
(Accessed 09 Apr 2022)
Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: A longitudinal, population-based linked cohort study
Damien Foo, Mohinder Sarna, Gavin Pereira, Hannah C. Moore, Annette K. Regan
Research Article | published 05 Apr 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003963

PLOS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 09 Apr 2022)
[No new digest content identified]

PLOS One
http://www.plosone.org/
(Accessed 09 Apr 2022)
Research Article
The new normal: Covid-19 risk perceptions and support for continuing restrictions past vaccinations
Maja Graso
Research Article | published 08 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266602

Awareness, attitudes and acceptability of the HPV vaccine among female university students in Morocco
A. Yacouti, N. Elkhoudri, A. El got, A. Benider, F. Hadrya, R. Baddou, A. Forster, M. Mouallif
Research Article | published 08 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266081

The impact of mental distress on influenza vaccine coverage
Linda Hassouneh, Shira Dunsiger
Research Article | published 07 Apr 2022 PLOS ONE
COVID-19 vaccine acceptance, hesitancy, and associated factors among medical students in Sudan
Saud Mohammed Raja, Murwan Eissa Osman, Abdelmageed Osman Musa, Asim Abdelmoneim Hussien, Kabirat Yusuf
Research Article | published 07 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266670

The COVID-19 Vaccine: Trust, doubt, and hope for a future beyond the pandemic in Germany
Amelia Fiske, Franziska Schönweitz, Johanna Eichinger, Bettina Zimmermann, Nora Hangel, Anna Sierawska, Stuart McLennan, Alena Buyx
Research Article | published 07 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266659

Predicting willingness to be vaccinated for Covid-19: Evidence from New Zealand
Geoff Kaine, Vic Wright, Suzie Greenhalgh
Research Article | published 07 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266485

Video-based messages to reduce COVID-19 vaccine hesitancy and nudge vaccination intentions
Ulrich T. Jensen, Stephanie Ayers, Alexis M. Koskan
Research Article | published 06 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0265736

Knowledge, attitude, and practice of seasonal influenza and influenza vaccine immunization among people visiting primary healthcare centers in Riyadh, Saudi Arabia
Norah Alhatim, Ahmad M. Al-Bashaireh, Ola Alqudah
Research Article | published 04 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266440

Impact of correcting misinformation on social disruption
Ryusuke Iizuka, Fujio Toriumi, Mao Nishiguchi, Masanori Takano, Mitsuo Yoshida
Research Article | published 04 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0265734

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 09 Apr 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
March 29, 2022 | vol. 119 | no. 13
Research Article
March 22, 2022  Coronavirus (COVID-19) Open Access
Opposition to voluntary and mandated COVID-19 vaccination as a dynamic process: Evidence and policy implications of changing beliefs
COVID-19 vaccination rates slowed in many countries during the second half of 2021, along with the emergence of vocal opposition, particularly to mandated vaccinations. Who are those resisting vaccination? Under what conditions do they change their minds? ...
Katrin Schmelz and Samuel Bowles

Research Article
March 23, 2022
A single-shot vaccine approach for the universal influenza A vaccine candidate M2e
Influenza, commonly referred to as “flu,” is a major global public health concern and a huge economic burden to societies. Current influenza vaccines need to be updated annually to match circulating strains, resulting in low take-up rates and poor ...
Ranmali Kavishna, Tha Yang Kang, [... ] Sylvie Alonso

Prehospital & Disaster Medicine
Volume 37 - Issue 2 - April 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 157   April 2022
[Reviewed earlier]

Proceedings of the Royal Society B
13 April 2022  Volume 289  Issue 1972
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 205  Pages e1-e30, 1-216 (April 2022)
Editorial  Full text access
Living with endemic COVID-19
A.C.K. Lee, J.R. Morling
Pages 26-27

Review article  Abstract only
Machine learning for predicting chronic diseases: a systematic review
F.M. Delpino, Â.K. Costa, S.R. Farias, A.D.P. Chiavegatto Filho, ... B.P. Nunes
Pages 14-25
Public attitudes and influencing factors toward COVID-19 vaccination for adolescents/children: a scoping review
Y. Liu, Q. Ma, H. Liu, Z. Guo
Pages 169-181

The Serbian COVID-19 Stress Scale and vaccine acceptance: is there a place for COVID-19-related distress in explaining attitudes towards vaccination?
Pages 37-42

Public Health Ethics
Volume 14, Issue 3, November 2021
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 2, March/April 2022
https://journals.sagepub.com/toc/phrg/137/2
[Reviewed earlier]

Qualitative Health Research
Volume 32 Issue 4, March 2022
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 18 Issue 2, April 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 09 Apr 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
Management and impact of interventions to reduce COVID-19 cases in Costa Rica

Risk Analysis
Volume 42, Issue 2  February 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Uncertainty in Risk Analysis: Bridging Science, Management and Communication
[New issue; No digest content identified]

Risk Management and Healthcare Policy
[ Accessed 09 Apr 2022]
[No new digest content identified]

Science
Volume 376| Issue 6589| 8 Apr 2022
https://www.science.org/toc/science/current
Editorial
New goals for science philanthropy
BY France A. Córdova
07 Apr 2022

Science Translational Medicine
Volume 14| Issue 638| 30 Mar 2022
https://www.science.org/toc/stm/current
Reviews
Point-of-care diagnostic tests for tuberculosis disease
BY Jia Mei Hong, et al.
06 Apr 2022
Advances in biomarkers and microfluidics technology facilitate the development of TB disease diagnostic point-of-care tests.

Social Science & Medicine
Volume 294  February 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 09 Apr 2022]
Theoretical Medicine and Bioethics
Volume 42, issue 3-4, August 2021
Special Issue: A plea for an experimental philosophy of medicine
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 46 March–April 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 3 Pages: i-iv, 217-336 March 2022
https://onlinelibrary.wiley.com/toc/13653156/current
RESEARCH ARTICLES
[Reviewed earlier]

Vaccine
Volume 40, Issue 12 Pages 1681-1912 (15 March 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/12
Conference info  Open access
Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP):
Tuberculosis vaccines intended for adults and adolescents as a test case
Sonali Kochhar, Draurio Barreira, Pauline Beattie, Marco Cavalieri, ... Birgitte Giersing
Pages 1681-1690
Discussion  Full text access
Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low
Kristin K. Gaffney, M. Jana Broadhurst, David M. Brett-Major
Pages 1691-1694
Discussion  Full text access
Vaccine supply chain: Resilience-by-design and resilience-by-intervention
Benjamin D. Trump, Maureen S. Golan, Jeffrey M. Keisler, Jeffrey C. Cegan, Igor Linkov
Pages 1695-1698
Research article  Open access
Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework
Frédéric Debellut, Rouden Mkisi, Vincent Masoo, Mike Chisema, ... Clint Pecenka
Pages 1741-1746
Research article  Full text access  
**Myocarditis following mRNA Covid-19 vaccination: A pooled analysis**  
Ioannis Bellos, Vasilios Karageorgiou, Dana Viskin  
Pages 1768-1774  

Research article  Full text access  
**Towards a predictive model of COVID-19 vaccine hesitancy among American adults**  
Jack Mewhirter, Mustafa Sagir, Rebecca Sanders  
Pages 1783-1789  

Research article  Open access  
**Impact of the COVID-19 pandemic on routine immunization coverage in children under 2 years old in Ontario, Canada: A retrospective cohort study**  
Catherine Ji, Pierre-Philippe Piché-Renaud, Jemisha Apajee, Ellen Stephenson, ... Karen Tu  
Pages 1790-1798  

Research article  Full text access  
**Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey**  
Özlem Akgün, Güzşah Kavrul Kayaalp, Fatma Gül Demirkan, Figen Çakmak, ... Nuray Aktay Ayaz  
Pages 1829-1836  

Research article  Full text access  
**The role of perceived social norms in college student vaccine hesitancy: Implications for COVID-19 prevention strategies**  
Anna E. Jaffe, Scott Graupensperger, Jessica A. Blayney, Jennifer C. Duckworth, Cynthia A. Stappenbeck  
Pages 1888-1895  

Research article  Full text access  
**Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically right-wing citizens**  
T. Winter, B.C. Riordan, D. Scarf, P.E. Jose  
Pages 1896-1903  

**Value in Health**  
April 2022  Volume 25  Issue 4  p473-676  
https://www.valueinhealthjournal.com/current  
[Reviewed earlier]  

:::::::  
:::::::  

**Pre-Print Servers**  

**Gates Open Research**
COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study
Koji Mori, Takahiro Mori, Tomohisa Nagata, Hajime Ando, Ayako Hino, Seiichiro Tateishi, Mayumi Tsuji, Keiji Muramatsu, Yoshihisa Fujino, the CORoNa Work Project
medRxiv 2022.03.30.22273203; doi: https://doi.org/10.1101/2022.03.30.22273203 Revision

Trans-border transfer of human biological materials in collaborative biobanking research: Perceptions and experiences of researchers in Uganda
Erisa Sabakaki Mwaka, Ian Guyton Munabi
medRxiv 2022.04.01.22273073; doi: https://doi.org/10.1101/2022.04.01.22273073

Effectiveness of a nation-wide COVID-19 vaccination program in Mexico
medRxiv 2022.04.04.22273330; doi: https://doi.org/10.1101/2022.04.04.22273330

The trustworthiness and impact of trial preprints for COVID-19 decision-making: A methodological study
Dena Zeraatkar, Tyler Pitre, Gareth Leung, Ellen Cusano, Arnav Agarwal, Faran Khalid, Zaira Escamilla, Matthew Cooper, Maryam Ghadimi, Ying Wang, Francisca Verdugo, Gabriel Rada, Elena Kum, Anila Qasim, Jessica J Bartoszko, Reed Siemieniuk, Chirag J. Patel, Gordon Guyatt, Romina Brignardello-Petersen
medRxiv 2022.04.04.22273372; doi: https://doi.org/10.1101/2022.04.04.22273372

Wastewater sequencing uncovers early, cryptic SARS-CoV-2 variant transmission
Wellcome Open Research  [to 09 Apr 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 09 Apr 2022]
Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics
Revised
A survey to gather perspectives of DBT/Wellcome Trust India Alliance-funded researchers on public engagement with science [version 2; peer review: 2 approved with reservations]
Sarah Iqbal, Banya Kar
Peer Reviewers Marina Joubert; Mary Chambers and Han Dong Thai Tran
Funder
DBT/Wellcome Trust India Alliance
LATEST VERSION PUBLISHED 08 Apr 2022

Systematic Review metrics
Revised
Incentivising research data sharing: a scoping review [version 2; peer review: 3 approved]
Helen Buckley Woods, Stephen Pinfield
Peer Reviewers Cameron Neylon; Carol Tenopir; Birgit Schmidt
Funder
Wellcome
LATEST VERSION PUBLISHED 06 Apr 2022

Study Protocol metrics
Revised
“AMR Dialogues”: a public engagement initiative to shape policies and solutions on antimicrobial resistance (AMR) in Thailand [version 2; peer review: 1 approved, 1 approved with reservations]
Tassawan Poomchaichote, Anne Osterrieder, Ravikanya Prapharsavat, Bhensri Naemiratch, Supanat Ruangkajorn, Chaiwat Thirapantu, Kamjariya Sukrung, Niyada Kiatying-Angsulee, Nithima Sumpradit, Sirima Punnin, Direk Limmathurotsakul, Phaik Yeong Cheah
Peer Reviewers David Kaawa-Mafigiri; Papreen Nahar
Funder
Wellcome Trust
LATEST VERSION PUBLISHED 07 Apr 2022

* * * * *

Think Tanks
Policy Actions for the US Government to Accelerate Access to Oral Antivirals for COVID-19 in Low- and Middle-Income Countries

Javier Guzman et al.
April 07, 2022

While oral antivirals are not a substitute for vaccination, they are key to preventing severe illness, saving lives, and preserving health systems. Vaccination rates continue to be low in low-income countries; only 14 percent of the population in low-income countries has received one dose of the vac...

Ending COVID-19 Emergency Declarations Will Bring an End to Flexibilities that Aided Patients, Providers, Insurers, and Public Programs in Responding to the Pandemic

When the federal government ends COVID-19 emergency declarations that were declared in the early days of the pandemic, it will bring to a close several changes that were enacted temporarily to enable the U.S. health care system to better deal with the crisis. A new KFF resource details a number...

As the COVID-19 Pandemic Enters the Third Year Most Adults Say They Have Not Fully Returned to Pre-Pandemic ‘Normal’
People of Color, Lower Income Adults, and Those With Chronic Conditions Are More Vigilant About COVID-19 Precautions Like Masking, and Want Others to Continue Them as Well The Public Is Divided About Public Transportation Mask Requirement, With Half Wanting the Mandate Extended and the Other Half Wanting to Let it...

**ODI [Overseas Development Institute] [to 09 Apr 2022]**
*Publications*
**Monitoring G20 contributions to global Covid-19 vaccine equity: issues and options**
28 March 2022
*Briefing/policy papers*
**Key messages**
- A focus on the systematic monitoring of G20 country policy responses to Covid-19 facilitates better understanding of the extent to which they have supported health equity globally and where they fall short and highlights actions G20 countries can take to place equity at the front and centre of recovery efforts.
- Any efforts to construct a composite index must consider carefully how to treat the indicators, weight indicators and dimensions, and aggregate the data; the brief outlines options and their implications.
- Efforts to monitor G20’s Covid-19 response are beset by limitations, not least the absence of indicators on actions no member country has taken, such as compelling pharmaceutical companies to share vaccines, knowledge and patents with poorer countries.
- The available data reveals huge variation in G20 country performance, irrespective of their incomes, and between what countries have done and what they could have done to advance equity.

**Rand [to 09 Apr 2022]**
https://www.rand.org/pubs.html
*Reports, Selected Journal Articles*
[No new digest content identified]*

---

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.
Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.